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The aim of this review is to provide a comprehensive examination of the current literature
describing the neural-immune interactions, with emphasis on the most recent findings of
the effects of neurohormones on immune system. Particularly, the role of hypothalamic
hormones such as Thyrotropin-releasing hormone (TRH), Corticotropin-releasing hormone
(CRH) and Gonadotropin-releasing hormone (GnRH). In the past few years, interest has
been raised in extrapituitary actions of these neurohormones due to their receptors
have been found in many non-pituitary tissues. Also, the receptors are present in
immune cells, suggesting an autocrine or paracrine role within the immune system. In
general, these neurohormones have been reported to exert immunomodulatory effects
on cell proliferation, immune mediators release and cell function. The implications of
these findings in understanding the network of hypothalamic neuropeptides and immune
system are discussed.
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INTRODUCTION
The neurosecretion in the hypothalamus can be traced back to the
work of Scharrer and Scharrer (1940). Posterior studies by Harris
specified that the hypothalamic substances secreted into the portal
vessels were pituitary specific and propose the concept of “releas-
ing factors” whose purpose was to initiate a cascade of events
resulting in the release of peripherally active hormones (Harris,
1948).
The discovery and chemical characterization of the first iden-
tified hypothalamic releasing factor by Burgus et al. (1969) and
Boler et al. (1969) provided ultimate confirmation for the found-
ing principles of neuroendocrinology and was followed by the
discovery of other peptide-releasing factors (Nillni and Sevarino,
1999).
THYROTROPIN-RELEASING HORMONE (TRH)
TRH, the smallest known peptide hypophyseotropic hormone, is
a tripeptide (pGlu-His-Pro-NH2; where pGlu stands for pyrog-
lutamic acid) that is released from the hypothalamus and trans-
ported via the portal vascular system to the anterior pituitary
where it stimulates the release of thyroid-stimulating hormone
(TSH) and prolactin from the anterior pituitary (Matre et al.,
2003).
TRH it is also known as thyrotropin-releasing factor (TRF),
thyroliberin or protirelin (Khomane et al., 2011) and was the
first chemically defined hypophyseotropic hormone (Bílek et al.,
2011).
SYNTHESIS
This small tripeptide (362.42 Da) is indeed processed from a
larger precursor protein, prepro-TRH (ppTRH), through now
classic cleavage mechanisms, C-terminal amidation, and cycliza-
tion of the N-terminal Gln to pGlu (Guillemin, 2005).
The rat ppTRH is a 29 kDa polypeptide composed of 255
amino acids. The rat precursor contains an N-terminal 25-amino-
acid leader sequence, five copies of the TRH progenitor sequence
Gln-His-Pro-Gly flanked by paired basic amino acids (Lys-Arg
or Arg-Arg), four non-TRH peptides lying between the TRH
progenitors, an N-terminal flanking peptide, and a C-terminal
flanking peptide. Rats and mice have five Gln-His-Pro-Gly TRH
progenitor sequences, whereas humans have six TRH sequences
(Chiamolera and Wondisford, 2009).
TRH EXPRESSION REGULATION
The maintenance of euthyroidism is dependent on a highly regu-
lated balance of neuropeptides and neurotransmitters, where the
dominant positive hypothalamic control for TSH is TRH, and the
principal feedback control is through thyroid hormones (THs)
(Nillni and Sevarino, 1999).
THs exert powerful feedback inhibition over the TRH response
system by inhibiting TRH synthesis and processing in TRH neu-
rons in the paraventricular region of the hypothalamus and
decreasing TRH receptors (TRHR) and responses in the pituitary
gland (Hinkle et al., 2012).
TRH gene expression is also regulated by temperature, food
intake, and stress. Thus the TRH neuron is well positioned to inte-
grate information about the environment as well as circulating
TH levels and ultimately affect metabolism in response to these
physiological changes (Chiamolera and Wondisford, 2009).
HALF-LIFE
The short half-life (4–5 mins) of TRH is most likely due to rapid
degradation of the TRH at both the carboxy (COOH) and
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amino (NH2) termini. Cleavage of the pyroglutamyl moiety of
TRH by enzymes like aminopeptidases and deamidases causes
formation of the metabolite histidyl proline diketopiperazine
(ClycoHistine-Proline, CHP) while its deamidation results in the
formation of the free acid, that is, TRH-OH (Khomane et al.,
2011).
TRHR
The TRHR is a member of a large family of transmembrane
proteins (G-protein-coupled receptors, GPCRs) for which an
interaction with an intracellular G protein is a critical part of
the signal transduction pathway mediated by the receptor. It
is thought that all GPCRs have a common tertiary structure
composed of seven transmembrane helices. The topology of
these membrane-bound proteins is defined by an extracellular
amino terminus and an intracellular COOH terminus. Conse-
quently, the helices are connected by intracellular-extracellular
loops. Colson et al. (1998) suggested that TRH initially interacts
with residues within the extracellular loops and then moves into
the transmembrane binding pocket, aided by the motion of the
loops.
A single TRHR gene has been found in humans and
higher mammals and two genes encoding homologous recep-
tors, TRHR1 and TRHR2, in rodents (Sun et al., 2003). TRHR1
predominates in the anterior pituitary gland while both TRHR1
and TRHR2 are found in rodent central nervous system (CNS)
(Hinkle et al., 2012).
EXTRAHYPOTHALAMIC AND EXTRAPITUITARY LOCATION OF TRH AND
TRHR RESPECTIVELY
Originally discovered in the hypothalamus, consistent with
its classical role as a hypothalamic hypophysiotrophic factor,
TRH and TRHR are now known to be distributed through-
out the central and peripheral nervous system (PNS) and are
found extensively in extrahypothalamic brain structures and
in other organs and tissues (Sun et al., 2003; Kamath et al.,
2009).
TRH OUTSIDE THE PITUITARY ZONE
TRH has been located in several brain areas other than the par-
aventricular nucleus as well as in non-CNS tissues:
• Pancreatic β-cells (Engler et al., 1981; Kawano et al., 1983).
• The whole gastrointestinal tract where it may modulate con-
tractions (Morley, 1979; Engler et al., 1981).
• The genitourinary system. TRH is found in rat, canine
and human prostate, seminal vesicles, ovary, testis, Leydig
cells and epididymis (Pekary et al., 1980, 1983a,b; Feng et al.,
1992).
• The presence of TRH in rat, human, porcine and bovine
retina has been reported (Schaeffer et al., 1977; Martino et al.,
1980a,b).
• Shambaugh et al. (1979) identified TRH activity in placental
extracts by specific radioimmunoassay test (RIA).
• TRH has been found as part of immune system tissues and
blood elements (Matre et al., 2003). This topic will be discussed
in depth in the following sections.
TRHR OUTSIDE THE HYPOTHALAMIC ZONE
Besides the well-known TRHR location in the pituitary zone,
TRH binding sites have been described throughout the central
and PNS and in non-CNS tissues including:
• Uterus, ovary and testis where TRHRmRNA levels appear to be
relatively high (Fukusumi et al., 1995; Montagne et al., 1999).
• Wang et al. (1997) reported that small intestine epithelial cells
were found to express receptors for TRH and to be a primary
source of intestine-derived TSH.
• TRHR is also found in retina (Satoh et al., 1993) and adrenal
gland (Montagne et al., 1999).
Furthermore, TRHR expression in organs and cells of the
immune system has been confirmed:
• Expression of TRHR mRNA and TRHR in lymphoid tissues
has been found: Thymus, mesenteric lymph nodes and spleen
(Raiden et al., 1995; Mellado et al., 1999).
• Thymus expression of the TRHR has been reported by
several authors (Fukusumi et al., 1995; Mellado et al., 1999;
Montagne et al., 1999; Matre et al., 2003).
• Expression analysis in rat demonstrated the presence of
TRHR mRNA in bone marrow (Montagne et al., 1999;
Matre et al., 2003) and in the rat natural-killer cell line RNK-
16 (Matre et al., 2003). This expression was shown to be func-
tional as evidenced by TRH binding to surface receptors
on thymocytes and RNK-16 cells.
• Analysis of human peripheral blood lymphocyte (Raiden et al.,
1995; Mellado et al., 1999) and tonsil-derived leukocyte pop-
ulations showed TRHR expression in non-activated and
phytohemagglutinin-activated T and B cells (Mellado et al.,
1999).
The widespread distribution of TRH and the TRHR within
and outside the CNS supports a diverse range of roles for
this molecule, roles likely to involve many functions outside
of the traditional hypothalamic-pituitary-thyroid (HPT) axis
(Nillni and Sevarino, 1999).
TRH FUNCTIONS
TRH indirectly stimulates TH biosynthesis and release. Thus,
TRH is central in regulating the HPT axis. TRH influences
the release of other hormones, including prolactin, growth hor-
mone, vasopressin, insulin, and the classic neurotransmitters
noradrenaline and adrenaline (Nillni and Sevarino, 1999).
EXTRAHYPOPHYSIOTROPIC FUNCTIONS OF TRH
More than two-thirds of immunoreactive-TRH in the brain
is found outside of the traditional “thyrotrophic zone” of the
hypothalamus. This extrahypophysiotropic TRH is believed to
function as a neuromodulator of known neurotransmitters.
Indeed, it might act as a neurotransmitter itself; it is present in
secretory granules whose exocytosis is responsive to membrane
depolarization, it acts through specific receptors that are widely
distributed throughout the CNS, and it is rapidly cleared through
specific catabolic pathways. In several areas of the brain, TRH is
colocalized with other neurotransmitters and/or neuromodula-
tors (Nillni and Sevarino, 1999).
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These effects of TRH have been demonstrated using TRH
and/or TRH analogs. Available TRH analogs have higher affini-
ties for the TRHR, longer half-lives, etc. (Engel et al., 2006;
Khomane et al., 2011; Monga et al., 2011).
Beside endocrine functions, TRH also possesses several neu-
ropharmacological effects like cerebral nerve activation (stimula-
tion of motor function), effects on sympathetic nervous system
(elevation of blood pressure and stimulation of respiratory),
effects on spinal function (stimulation of spinal motor neuron),
effects on CNS (antidepressant activity) and peripheral actions
(suppression of gastric acid secretion, stimulation of glucagon
secretion). These CNS-mediated effects provide the rationale for
the use of TRH in the treatment of brain/spinal injury and cer-
tain CNS disorders, including schizophrenia, Alzheimer’s disease,
epilepsy, amyotrophic lateral sclerosis, Parkinson’s disease and
depression (Khomane et al., 2011).
TRH AND IMMUNE SYSTEM
Two-way communication between the immune and neuroen-
docrine systems is now well recognized. These interactions are
mediated by cytokines, neuropeptides, hormones, other soluble
factors and their receptors (Grasso et al., 1998).
As mentioned above, cells of the immune system have been
found to contain receptors for neuroendocrine hormones and can
also be considered a source of pituitary and hypothalamic pep-
tides (Matre et al., 2003).
IMMUNE RESPONSE TO TRH ADMINISTRATION
Proliferation
Induction. Acute and chronic administration of TRH enhances
the proliferation of splenic and thymic lymphocytes in rats
(Pawlikowski et al., 1992; Raiden et al., 1995; Winczyk and
Pawlikowski, 2000). In fact, it has been reported that TRH
promotes thymic reconstitution in mice with anterior hypotha-
lamic area lesions (Lesnikov et al., 1991). According with these
data, it was also reported that TRH enhances the in vitro
plaque-forming cell response (Kruger et al., 1989), antagonizes
the dexometasone-induced thymocyte and splenocyte sup-
pression (Winczyk and Pawlikowski, 2000) and administration
in humans led to increased secretion of IL-2 into the blood
(Komorowski et al., 1993).
Suppression. It has also been reported that TRH significantly
inhibits monocyte activity (Lersch et al., 1989). The experimental
work of Kunert-Radek et al. (1991) addressed the proliferation of
murine splenocytes in vitro considering the 3H-thymidine incor-
poration into splenocyte DNA as an index of proliferation. They
found that TRH suppressed the proliferation of splenocytes.
TRH has the capability to modulate the natural cell-mediated
cytotoxicity. To try it out, TRH was added to the feed of
White Leghorn male chicks and peripheral blood lympho-
cytes were cultured in vitro with or without different mitogens
(Phytohaemagglutinin-A (PHA), ConA, or Lipopolysaccharide
(LPS)), and the culture supernatants were tested for the presence
of lymphokines. Results showed that the supernatant from in vivo
5 ppmTRH-treated lymphocytes significantly suppressed the nat-
ural cell-mediated cytotoxicity (Haddad and Mashaly, 1992).
Recently was published that oral administration of TRH in
mice with experimental autoimmune encephalomyelitis (EAE),
an animal model of multiple sclerosis, reduces the spinal cord
inflammatory foci without increased frequency of regulatory T
cells (Treg) in spleen (Brod and Bauer, 2013).
Induces TSH production by immune cells
At very low concentrations, TRH induces splenocyte production
of TSH in vitro (Kruger et al., 1989).
Peripheral blood mononuclear cells (PBMC), rat splenocytes
and transformed T cell lines produce TSH in response to TRH
(Harbour et al., 1989; Raiden et al., 1995).
Induces immune mediators production
PBMC, rat splenocytes and transformed T cell lines can enhance
or modulate the in vitro antibody response in response to TRH
(Kruger et al., 1989; Hart et al., 1990).
Koshida and Kotake (1993) investigated the role of TRH
on the superoxide anion (O2−) production of rabbit peri-
toneal macrophages. Their results showed that TRH acts on
macrophages and suggest that TRH possesses the priming action
of O2− release in response to the chemotactic peptide N-
formyl-methionyl-leucyl-phenylalanine, and opsonized zymosan.
Authors suggest that if this type of priming exists in vivo there
should be a role to play in an inflammation process.
In vitro studies have shown that a TRH fixation occurs at
the level of the human polymorphonuclear neutrophil, which
suggests putative membrane receptor (s) for the hypothala-
mic hormone. The correspondent in vivo analyses demonstrated
that after TRH administration, enzyme modifications (myeloper-
oxydase, alkaline phosphatase) and metabolism changes (PAS,
Sudan black) happen, showing a functional activation of that
blood cell (Blum et al., 1976). These in vivo effects could be
due to TRH is being directly attached to its receptor on
neutrophils or an indirect effect is being mediated by TSH
or THs.
Intravenous bolus of TRH in normoprolactinemic women
increases plasma gamma interferon (IFN-γ ) levels 45 mins after
administration. In order to investigate a possible direct action of
TRH on immune cells, the authors also examined the effects of
this hypothalamic peptide on IFN-γ production by PBMCs stim-
ulated in vitro with suboptimal concentration of bacterial super-
antigen staphylococcal enterotoxin A or concanavalin A (ConA),
collected before the intravenous administration of TRH. The in
vitro findings showed a directly enhanced IFN-γ production by
activated lymphocytes (Grasso et al., 1998).
Furthermore, splenic and CNS lymphocytes showed signifi-
cant decrease in levels of profile 17 helper t cells (TH17) and TH1
cytokines: Interleukin-17 (IL-17), tumor necrosis factor (TNF-α)
and IL-2 respectively, after oral administration of TRH in EAE
mice. This treatment also increased CNS lymphocyte produc-
tion of TH2 cytokines, in particular IL-13 (Brod and Bauer, 2013).
Thus, oral TRH shows a unique pattern of immunomodulation
for an ingested neuropeptide although the poor oral bioavailabil-
ity associated with TRH and some of its analogs (Khomane et al.,
2011).
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TRH expression response against immune system challenges
It is known that high concentrations of TRH seem to decrease
the production of antibodies against sheep red blood cells (SRBC)
(Kukain et al., 1982).
Pérez Castro et al. (1999) investigated whether TRH mRNA
levels in the hypothalamus are altered after SRBC (a T cell-
dependent antigen) immunization. An increased level of TRH
mRNA detected by Northern blot autoradiography was observed
at 4, 6, and 24 h post immunization in SRBC-injected animals.
The SRBC-induced effects on TRH mRNA levels are opposite
to those induced by LPS, a T cell-independent response through
macrophage and B lymphocyte activation. LPS induces a decrease
in hypothalamic TRH mRNA levels that is observed at 24 h and
more pronounced at 4 h (Pérez Castro et al., 1999).
As we can see, TRH effects could seem controversial but
is important to consider that interactions between the CNS,
the endocrine system and the immune system are mediated at
multiple levels. These mediators include secreted chemical mes-
sengers such as hormones, cytokines, neurotransmitters and neu-
ropeptides acting directly or via the nervous system.
Evidence indicates interactions at the level of receptors (e.g.,
the presence of neuroendocrine peptide receptors on immune
cells), at the level of secretory function (e.g., the synthesis and
secretion of neuroendocrine peptides by immune cells), and at
the level of signal transduction (Kamath et al., 2009). Integration
of these complex interactions in a single route would be inac-
curate, for this reason, the most wise conclusion could be con-
sider the TRH-immune system homeostatic hypothesis proposed
by Gary et al. (2003) and Kamath et al. (2009), which states that
TRH mediated mechanisms respond to many elements of the
immune system and affect them in ways that tend to maintain
or restore homeostasis.
The effects of TRH administration on immune system are
summarized in Figure 1.
CLINICAL RELEVANCE AND FUTURE DIRECTIONS
Studies on the effects of TRH in vitro hardly can be extrap-
olated to in vivo conditions. The direct effect of TRH on
the immune system provides a modulatory physiological role.
However, pharmacological administration in humans and in
experimental animals involves two pathways impact (1) through
stimulation of TSH secretion and therefore of THs and (2) the
direct effect on the immune system. TRH administration may
affect these two ways and with addition or synergy effects. One
possibility to explore the direct mode might be using hypophy-
sectomized or thyroidectomized animals to avoid endocrine
influence. According to the studies described above, it is possible
to consider the possibility that clinical treatment with TRH may
improve the immune response in patients with immune deficien-
cies or reduced response in autoimmune diseases such as mul-
tiple sclerosis or lupus erythematosus. Such expectations are a
challenge to be explored in the future.
CORTICOTROPIN-RELEASING HORMONE (CRH)
CRH or Corticotropin-releasing factor (CRF) was characterized,
purified and synthesized in 1981 by Vale. The composition of this
41 amino-acid peptide is different from one species to another.
Its principal origin in the brain are the neurons from paraventric-
ular nucleus of the hypothalamus. By the portal hypothalamic-
pituitary vessels, it reaches the anterior pituitary lobe where it
stimulates the corticotroph cells (Raux-Demay and Girard, 1985;
Emeric-Sauval, 1986). The plasma half-life of CRH in humans is
4 mins (Schürmeyer et al., 1984). The action of CRH on adreno-
corticotrophic hormone (ACTH) secretion is predominant, but
it acts in relation with arginine-vasopressin and potentially with
angiotensin and catecholamines. Adrenal steroids (glucocorti-
coids) act on feedback control of CRH secretion in the hypotha-
lamus and also on pituitary corticotrophs. CRH has shown to be
an important regulator of the endocrine stress response, and it
is now known to play a role in diverse functions in the homeo-
static balance, important in mobilization of resources and behav-
iors during stress (Bale and Vale, 2004), it is involved in the reg-
ulation of food intake and satiety, as well as gastrointestinal
tract motility, vascular tone, and development, and also acoustic
and cardiac function (Heinrichs et al., 1992; Koob and Heinrichs,
1999; Maillot et al., 2000; Inoue et al., 2003; Janssen and Kozicz,
2013).
CRH RECEPTOR (CRHR)
High-affinity CRHRs which mediate the actions of the hypotha-
lamic peptide on ACTH release, have been principal identified in
the anterior pituitary gland. Interaction of the pituitary receptor
by CRH agonists stimulates ACTH release. CRH exerts its effects
by binding to specific cell surface receptors, of which two receptor
subtypes have been reported, CRH-R1 and CRH-R2. These recep-
tors share high sequence homology and belong to the family of
seven transmembrane GPCRs (Vaughan et al., 1995; Lewis et al.,
2001).
Actions of this peptide are initiated by binding and acti-
vating GPCRs and subsequently the activation of adenylate
cyclase and cyclic adenosine monophosphate dependent protein
kinase (Grammatopoulos and Chrousos, 2002). In the regulation
of ACTH secretion, the effects of CRH on the corticotroph
are integrated with the stimulatory actions of cyclic adenosine
monophosphate and the inhibitory effects of glucocorticoids. Fol-
lowing adrenalectomy, the progressive elevation of plasma ACTH
levels is accompanied by a concomitant decrease in pituitary
CRHRs (down-regulation) (Wynn et al., 1985; Aguilera et al.,
1986).
Extrapituitary expression of CRHR
CRH-R1 is a 415 amino acid peptide and has a wide-
spread expression in stress-related areas located in the CNS
(Justice et al., 2008; Kuhne et al., 2012). Outside the CNS, the
CRH-R1 is expressed in the adrenal gland, gastrointestinal
tissue, ovary, testis, skin, thymus and spleen (Dufau et al., 1993;
Nappi and Rivest, 1995; Slominski et al., 1995; Baigent and
Lowry, 2000; Müller et al., 2001; Chatzaki et al., 2004). CRH-R2
is a 397–437 amino acid protein and it is abundantly expressed
in the CNS (Korosi et al., 2007; Justice et al., 2008; Kuhne et al.,
2012). In the periphery, the receptor has been identified in the
retina, heart, skeletal muscle, vasculature, adrenal gland, and
gastrointestinal tissue (Lovenberg et al., 1995; Müller et al., 2001;
Chatzaki et al., 2004).
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FIGURE 1 | Immune response against Thyrotropin-Releasing Hormone/Thyrotropin-Releasing Hormone agonist administration in a diversity of
normal and pathological conditions (↑ = increase, ↓ = decrease).
Binding sites for CRH have been reported on adher-
ent splenocytes (Webster et al., 1990), monocyte-macrophages
(Audhya et al., 1991) and T lymphocytes (Singh and Fudenberg,
1988). CRH-R1 and CRH-R2 expression was described in granu-
locytes and lymphocytes in inflamed tissues (Mousa et al., 2003).
CRH-R1 mRNA expression had been reported in the human
leukemic mast cell line (Theoharides et al., 1998) and mast cells
were reported to express immunoreactive CRH-R1 in inflamed
human synovial tissue (McEvoy et al., 2001).
CRH EFFECTS ON CNS AND PNS
Independently of anterior pituitary, CRH has effects within of
nervous system. The central administration of CRH produces
hypertension, tachycardia and an elevated oxygen consumption.
CRF acts within the brain to increase plasma concentrations
of noradrenaline and adrenaline resulting in increased plasma
concentrations of glucagon and in hyperglycemia. Likewise, also
acts increasing the plasma concentrations of vasopressin. CRH
induces a reduction in food intake and increases grooming behav-
ior and locomotor activity. The physiological significance of the
peripheral actions of CRH on various organ systems is unknown.
Intravenous administration of CRH reduces gastric acid secre-
tion, gastric emptying and blood pressure but increases heart
rate, venous return to the heart, mesenteric and aortic blood flow
and pancreatic bicarbonate and protein secretions (Lenz, 1987;
Chen et al., 2007).
CRH AND IMMUNE SYSTEM
The cellular components of the immune-inflammatory response
include leukocytes, such as monocytes–macrophages, polymor-
phonuclear neutrophils, eosinophils and basophils, platelets,
dentritic cells, mast cells, epithelial and endothelial cells, and
fibroblasts which belong to the innate immune system, as well as
lymphocytes T, B and natural killer (NK) which are included in
the adaptive immune system. These cells cooperate using molec-
ular signals, including ILs, colony-stimulating factors, TNF, IFNs,
Frontiers in Integrative Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 56 | 5
Quintanar and Guzmán-Soto Hypothalamic neurohormones and immune responses
transforming growth factor, and chemokines, vasoactive amines
(histamine and serotonine), plasma proteases (kinine and com-
plement systems), arachidonic acid metabolites (prostaglandins,
leukotrienes, and lipoxins), platelet-activating factor, nitric oxide,
and neuropeptides (Mastorakos et al., 2006).
The majority of in vivo studies suggest that direct stimula-
tion of hypothalamic CRH by cytokines is the principal route by
which immune activation stimulates the hypothalamic–pituitary–
adrenal (HPA) axis (Besedovsky et al., 1986; Harbuz et al., 1992)
and this process is prostaglandin-dependent. Thus, experimen-
tal evidence suggests that CRH may modulate the immune and
inflammatory responses via two pathways: an anti-inflammatory
one operated by centrally released CRH, most likely through
stimulation of glucocorticoid and catecholamine release, and one
pro-inflammatory, through direct action of peripherally secreted
CRH (Karalis et al., 1997).
CRH in immune cells
Mast cells. Mast cells are critical for allergic reactions due to
their secretion of numerous vasoactive molecules and cytokines
(Kobayashi et al., 2000). Evidence indicates that mast cells are
also involved in innate and acquired immunity (Marone et al.,
2002), as well as in neuroinflammatory conditions such as those
affected by stress (Theoharides and Cochrane, 2004). Mast cells
secrete numerous pro-inflammatory cytokines, such as IL-6, IL-
8, and TNF-α (Kobayashi et al., 2000; Marone et al., 2002), and
secretion of vascular endothelial growth factor (VEGF) by CRH
stimulation (Cao et al., 2005). Interestingly, human mast cells
were shown to synthesize and secrete large amounts of CRH,
suggesting that this peptide could regulate mast cells through
CRH receptor in an autocrine manner. Secretion of CRH from
mast cells could also be triggered by pro-inflammatory molecules
that are released during the initial phases of inflammation
(Kempuraj et al., 2004). CRH causes mast cell degranulation in
human skin, releasing great amounts of histamine, which appears
to be the principal mediator of the vasodilatory effects of CRH
(Wright, 2003).
Mononuclear cells. In mononuclear cells, it has been reported
that CRH stimulates immune functions, proliferation of lym-
phocytes both in the absence and presence of T cell mitogens,
and the expression of IL-2R antigen on T cells (Singh, 1989;
Singh et al., 1990). It has also been reported the presence of bind-
ing sites for CRH on monocytes, T and B lymphocytes and
thymus (Singh and Fudenberg, 1988). The CRH is also a stim-
ulator of production of two interleukins, IL-1 and IL-2. IL-1
has been shown to stimulate the secretion of CRH by hypotha-
lamic cells (Sapolsky et al., 1987) and CRH stimulates the pro-
duction of IL-1 and IL-2, suggesting the presence of a complete
network between the neuroendocrine system and the immune
system (Singh and Leu, 1990).
The release of CRH plays a role in modulating NK activ-
ity following stress also implies that CRH in the brain may
be involved in the functional population of lymphocytes. Stud-
ies have been conducted to analyze the effect of CRF on
the reduction of several cellular immune measures such as
splenic and peripheral blood NK activity and lymphocyte
responses to mitogenic stimulation (Strausbaug and Irwin, 1992;
Boyadjieva et al., 2006). Other observations also indicate that
central doses of CRH slow the kinetics and reduce the level
of IgG response to a specific T-cell-dependent antigen (Irwin,
1993). The administration of central CRH antagonist induces
suppression of NK cytotoxicity. In contrast, peripheral applica-
tion has no effect on CRH modulation of immunity (Irwin et al.,
1987).
Other studies have shown CRH to inhibit IFN-γ secretion
(Angioni et al., 1993). IL-2-induced splenocyte proliferation as
well as LPS-mediated IL-1 and IL-6 production by peripheral
blood monocytes (Hagan et al., 1992).
The effects of CRH were almost exclusively examined in the
mononuclear cells, however in other studies has been reported
that polymorphonuclear cells (neutrophils), express higher lev-
els of CRH-R1 than mononuclear immune cells in mouse
(Radulovic et al., 1999). It has been shown that CRH inhibits the
secretion of IL-1β frommature neutrophils purified from spleens
of mice injected with LPS (Radulovic and Spiess, 2001).
It has been described the CRH presence in macrophages
(Brouxhon et al., 1998). Results showed that CRH could be
detected in normal peritoneal macrophages and the levels
increased significantly after stimulation with LPS (Wang et al.,
2012). The role of CRHmay be immunomodulatory, however the
effects remains to be studied.
On other hand, studies shown that cluster of differentia-
tion (CD14+) group of cell surface marker proteins, the CRH
can activate CD14+ cells to produce TNF-α cells and compro-
mise endothelial barrier function by inducing apoptosis of the
endothelial cells (Song et al., 2013).
CRH and its relationship to immune therapies
Drugs have been proposed to either block CRHR-1 and CRHR-2
receptors as CRH inhibitors with therapeutic properties through
modifying the immune response as tool for both CNS and
inflammatory disorders associated with central and periph-
eral CRH. CRH-R1 antagonist could be considered for the
treatment of allergic conditions, such as urticaria, asthma,
eczema, or disorders that increase blood–brain barrier perme-
ability (Theoharides et al., 1998; Esposito et al., 2002), chronic
inflammatory bowel syndromes, irritable bowel disease, and
ulcerative colitis and other pathologies (Kawahito et al., 1995;
Gravanis and Margioris, 2005).
The effects of CRH administration on immune system are
summarized in Figure 2.
Future directions
There are two major problems associated with the HPA axis.
The inflammatory process and the reduction in the immune
response. Chronic exposure to antiinflammatory steroids have
effects such as immunosuppression which under certain con-
ditions can cause undesired effect. Identifying specific receptor
subtypes to CRH, or applying interleukin receptor blockers may
provide a viable alternative to maintaining of the homeostatic
mechanisms.
Emotional stress causes somatic alterations including the
immune response and is perhaps, one of the most pressing prob-
lems in global public health that needs to be addressed.
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FIGURE 2 | Experimental data of Corticotropin-Releasing Hormone/Corticotropin-ReleasingHormone agonist impact on immune system cells and
processes (↑ = increase, ↓ = decrease).
GONADOTROPIN-RELEASING HORMONE (GnRH)
GnRH, also known as luteinizing hormone releasing hormone
(LHRH), is a small peptide hormone (pGlu-His-Trp-Ser-Tyr-Gly-
Leu-Arg-Pro-Gly-NH2) of 1.2 kDa, with an established role as
central regulator of the neuroendocrine reproductive axis in both
males and females (Cheung and Wong, 2008).
This neuropeptide is mainly synthesized in hypothala-
mic neurons of the medial preoptic area. It is well estab-
lished that adenohypophysial gonadotropic cells stimulate the
synthesis and secretion of gonadotropic hormones such as follicle
stimulating hormone (FSH) and luteinizing hormone (LH)
(Cheng and Leung, 2005). LH and FSH are released into the
systemic circulation in a pulsatile pattern, which is dependent
upon the GnRH pulse frequency, and act to affect gonadal
steroidogenesis and gametogenesis (Sasaki and Norwitz, 2011).
GnRH ISOFORMS
At the present, it is known that, in addition to the hypothala-
mic GnRH, several other isoforms of the decapeptide exist in
vertebrates. All these isoforms are characterized by the conser-
vation of the length of the peptide as well as by the amino acid
sequences of the N-terminal (Glp-His-Trp-Ser) and C-terminal
(Pro-Gly-NH2) domains, indicating that these molecular features
are critical for the binding to, and the activation of, the recep-
tor (Limonta and Manea, 2013). The classical hypophysiotropic
GnRH located in the anterior hypothalamus/preoptic area is also
designed as GnRH-I (Stevenson et al., 2012).
A second isoform of GnRH, originally isolated from the
chicken hypothalamus and referred to as chicken GnRH or
cGnRH, has been isolated in most vertebrate species—including
humans—is now referred to as GnRH-II and is 70% homologous
to GnRH-I (Sasaki and Norwitz, 2011). GnRH-II is expressed at a
higher level outside of the brain (Tan and Bukulmez, 2011).
A third GnRH isoform, GnRH-III, was isolated from sea
lamprey and was also detected in the brain of mammals
(Tan and Bukulmez, 2011). This isoform has 60% homology with
GnRH-I. In the lamprey, GnRH-III is localized in brain areas
involved in the control of reproductive functions and it has been
reported to stimulate steroidogenesis and gametogenesis, but it
has 500–1000 times less potency in LH and FSH secretion both in
vitro and in vivo (Limonta and Manea, 2013).
GnRH is small and has good thermal and chemical stability
and no internal Cys bridges (minimal fixed structure). Its size
and stability has led to the availability of thousands of analogs
(Conn and Janovick, 2009).
SYNTHESIS AND SECRETION
GnRH is synthesized as a prohormone, human preproGnRH that
contains 92 amino acids (Harrison et al., 2004). The gene encod-
ing preproGnRH1 gene has been cloned in number of species and
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is approximately 4300-bp with four relatively short exons sepa-
rated by three large introns (Clarke and Pompolo, 2005).
Neurons that synthesize and release GnRH (GnRHergic neu-
rons) have their origin in embryonic olfactory placodes. These
embryonic cells, migrate and colonize the basal forebrain, pre-
optic area around the basal and medium hypothalamus. The
median eminence in mammals contains a large amount of GnRH,
so is the area in which the peptide is stored in neural termi-
nals before release into the hypothalamus-pituitary portal system
(Clarke and Pompolo, 2005).
GnRH is released as synchronized pulses from the nerve end-
ings of about 1000 neurons into the hypophyseal portal system
every 30–120 mins to stimulate the biosynthesis and secretion of
LH and FSH from gonadotrophs (Millar, 2005). In adult rodents,
GnRH is released from the median eminence at a frequency
of about one pulse every 30 mins. A slightly slower frequency
of release (approximately 50–60 mins intervals) is observed in
primates (Yin and Gore, 2006). On the other hand, continuous
(non-pulsatile) GnRH administration or long-lasting GnRH-a
desensitize GnRHR, thereby decreasing/inhibiting the release of
LH and FSH by the pituitary (Wilson et al., 2007).
HALF-LIFE
GnRH half-life normally is about 2–4 mins (Walters et al., 2008).
Its short half-life is because of the rapid cleavage of the bonds
between amino acids at positions 5–6, 6–7, and 9–10. Substitution
at position 6 in GnRH agonists (GnRH-a) yields them resistant
to degradation and increases its half-life and the time of receptor
occupancy (Magon, 2011).
GnRH RECEPTOR (GnRHR)
The human pituitary GnRHR belongs to the family of GPCRs
and is one of the smallest GPCRs (328 amino acid protein in the
human); it may contain only the essentials required for ligand
binding and signal transduction (Conn and Janovick, 2009).
Distinct forms of the GnRHR can be broadly divided into two
groups:
1. The type I GnRH-Rs have greater affinity for GnRH-I than for
GnRH-II and lacks a typical intracellular COOH terminus; this
group contains all knownmammalian GnRH-Rs except for the
recently described primate type II GnRH-R (McArdle et al.,
2002; Ciechanowska et al., 2010).
2. Type II GnRH-Rs have greater affinity for the GnRH-II and
possess C-terminal tails of varying length; this group contains
all the known receptors from non-mammalian vertebrates
(catfish, goldfish, chicken, goldfish, Xenopus, etc.) in addition
to the type II primate GnRH-Rs (McArdle et al., 2002).
EXTRAHYPOTHALAMIC AND EXTRAPITUITARY LOCATION OF GnRH
AND GnRHR RESPECTIVELY
GnRH outside the pituitary zone
GnRH has been located in several extrahypothalamic cells and
tissues: GnRH-like substances have been reported to be secreted
from tissues outside the CNS of rats and humans. Particu-
larly, a (GnRH)-like protein has been detected in human ovaries
(Aten et al., 1987; Dong et al., 1993; Peng et al., 1994). Also,
Oikawa demonstrated by PCR amplification of cDNA from rat
hypothalamus, granulosa cells, and whole ovary, a 241-bp prod-
uct identical to the authentic GnRH sequence based on analysis
on both strands (Oikawa et al., 1990).
RT-PCR analysis together with Southern blot analysis demon-
strated the presence of GnRH mRNA in human testes and mam-
mary gland (Dong et al., 1993).
Furthermore, the gene coding for GnRH is expressed in
immune tissue and immunoreactive GnRH is measurable in
immune cells. Analysis of mononuclear cells by RT-PCR coupled
to Southern hybridization of total RNA confirmed that GnRH
genes are expressed in human peripheral blood lymphocytes.
The GnRH transcripts in mononuclear cells were identical to the
hypothalamic GnRH and PRL release inhibiting factor cDNA, at
least within this 380-bp fragment (Chen et al., 1999).
Rat splenocytes contain an immunoactive and bioactive GnRH
(Emanuele et al., 1990; Azad et al., 1991) that has also been
found in lymphocytes from rat thymus (Marchetti et al., 1990;
Maier et al., 1992). Moreover, it has been reported that normal
and leukemic human T cells produce GnRH-II and GnRH-I and
that the incubation of those cells with these neuropeptides trig-
gered de novo gene transcription and cell-surface expression of a
67-kDa non-integrin laminin receptor that is involved in cellu-
lar adhesion and migration and in tumor invasion and metastasis
(Chen et al., 2002).
The fact that recent evidence shows the existence of diverse iso-
forms of GnRH, with high sequence homology and a core variable
region raises the issue that previous GnRH distribution studies
may have identified a variety of isoforms. To confirm the distri-
bution of GnRH-I only, Khan et al. (2003), reported that intense
GnRH-I immunoreactivity was found in Kupffer cells, and less
intense in spleen lymphocytes and follicular dendritic cells in rat.
Other cells that have been reported to express GnRH and its
mRNA are mast cells from the nervous system and the peri-
toneal cavity, as detected by immunohistochemistry and RT-
PCR, respectively (Silverman et al., 1994; Gill and Rissman, 1998;
Khalil et al., 2003).
Extrapituitary GnRHR
GnRH binding sites have been described throughout the CNS and
PNS as in several non-CNS cells and tissues:
Human ovarian granulosa-luteal cells also express the GnRHR
mRNA (Chen et al., 1999).
GnRHR expression in organs and cells of the immune system
has been confirmed: GnRH binding sites have been reported in
rat spleen (Batticane et al., 1991) and thymus, thus potentially
enabling GnRH-a to have direct stimulatory effects that might
contribute to improved T-cell function (Marchetti et al., 1989;
Batticane et al., 1991; Morale et al., 1991).
RT-PCR coupled to Southern hybridization of total RNA
obtained from mononuclear cells confirmed that the GnRHR is
expressed in human peripheral blood lymphocytes (Chen et al.,
1999) as in porcine lymphocytes (Standaert et al., 1992).
Chen and colleagues reported that the GnRHR transcript
expressed in mononuclear cells has an identical nucleotide
sequence as the pituitary GnRHR cDNA. In this work, a
time-course study of the effect of GnRH on mononuclear cells
was performed and it was found that GnRHR mRNA increased
gradually after in vitro culture, and this increase was further aug-
mented by treatment with GnRH for up to 24h. In contrast,
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the expression of GnRH mRNA was decreased by GnRH treat-
ment in a dose-dependent manner and the IL-2Rγ subunit gene
was highly expressed in mononuclear cells. At this point we can
speculate that these GnRH-binding sites in lymphocytes are prob-
ably functional, as many studies have demonstrated that GnRH-
a caused a dose-dependent increase in LH production, whereas
GnRHR antibodies blocked this action (Chen et al., 1999).
It has also been shown that blockade of central and peripheral
GnRHR with a potent GnRH antagonist (GnRH-ant) during a
critical period of maturation can impair the morphological devel-
opment of thymus and the cellular and humoral immune respon-
ses in rats (Morale et al., 1991) and monkeys (Mann et al., 1994).
Particularly, neonatal exposure of male primates to a GnRH-
ant alters early postnatal programming of immune function by
reducing the number of B cells and T cells in the thymic medulla
and T cells in the periarterial lymphatic sheaths of the spleen.
GnRH-ant treatment increased the frequency of clinical prob-
lems, lowered circulating levels of lymphocytes, total T cells,
CD8+ T cells and B cells, and altered the proliferative index of
lymphocytes to mitogens. As adults, the cell- and humorally-
mediated immune responses remained impaired (Mann et al.,
2000).
To evaluate regions of GnRH-I binding activity, a biotinylated
GnRH-I sequence was used with avidin-labelled HRP, and results
showed GnRH-I binding activity present in Kupffer cells, spleen
lymphocytes and follicular dendritic cells, as well as in thymocytes
and peripheral blood lymphocytes and neutrophils (Khan et al.,
2003).
GnRH AND IMMUNE SYSTEM
GnRH and sex steroids seem to be important components of
immune system modulation and may play a role in the regula-
tion of immune mediated diseases. A comprehensive description
of such interactions has been reviewed by Tanriverdi et al. (2003)
and Quintanar (2011).
Immune response to GnRH administration
Proliferation
Induction. When splenocytes and thymocytes are preincubated
with GnRH-a or GnRH peptide, an augmentation of the pro-
liferative response is obtained. Marchetti et al. (1989) showed a
significant dose-dependent increase on proliferative response to
the mitogen ConA in rat thymocytes. This response was abolished
with simultaneous addition of a GnRH-ant. Also, splenocytes and
thymocytes from proestrus female rats incubated with GnRH or
its analogs, significantly increased the basal proliferative activity
which was accompanied by a specific increase in IL-2 receptor-
positive cells (Batticane et al., 1991).
Furthermore, in vivoGnRH-a treatment prevents thymus atro-
phy and markedly stimulates thymocyte blastogenic activity in
hypophysectomized rats, thus suggesting that GnRH and its ago-
nistic analogs are may capable to exert a direct modulation of
immune system function (Marchetti et al., 1989).
Injection of GnRH-a increases CD8+ T-cell levels and prolif-
eration to a variety of mitogens (Mann et al., 1994). In another
study, it has been reported that GnRH immunization in rats
induced the presence of eosinophils in intertubular tissue of testes
whereas in unimmunized controls these cells were not present
(Duckett et al., 1997).
Moreover, in a rat model of pregnancy-induced thymic involu-
tion, GnRH-a infusions markedly attenuated pregnancy-induced
thymic involution resulting in significant increases in thymic
weight and thymocyte numbers (Dixit et al., 2003a).
In the same way, Sutherland et al. (2008) made a pilot study in
patients, where a GnRH-a (goserelin) was given prior to allogeneic
or autologous hematopoietic stem cell transplantation. GnRH-a
administration significantly increased neutrophil and lymphocyte
numbers within the first month of posttransplantation indicating
that either directly or indirectly, GnRH induced an increase in cir-
culating neutrophils.
It has been reported that treatment with the GnRH-a, leupro-
lide acetate (50 μg/mouse, s.c.) prior to restraint stress, signifi-
cantly prevented its effect on cell-mediated immunity, antibody
titer levels, total leukocyte count and relative thymus weight,
showing a significant increase of these immunological parameters
(Umathe et al., 2008).
Supression. To test whether a GnRH-a could alter in vivo human
immune cells, Ho et al. (1995) treated a group of infertile patients
under a protocol of buserelin acetate administration and periph-
eral B cells, NK cells, CD4+ and CD8+ T cells, and the expres-
sion of CD69, CD25, human leucocyte antigen-DR (HLA-DR),
and CD71 antigens on the T cells were serially examined by
dual-color flow cytometry. They found that the GnRH-a had a
transiently immunosuppressive effect on CD4+ and CD25+ T
cells, but CD69+, CD25+, and HLA-DR+ T cells were activated
during and after successful implantation. Regarding to the B cells,
NK cells, CD8+ T cells, and CD71+ T lymphocyte subpopulations
there were no changes throughout the whole course of treatment.
On the other hand, several groups have provided evidence
that the in vitro proliferation of a variety of human ovarian,
endometrial, and breast cancer cell lines can be inhibited by
agonistic and/or antagonistic analogs of GnRH in a dose- and
time-dependent manner (Eidne et al., 1987; Thompson et al.,
1991; Emons et al., 1993a,b; Emons and Schally, 1994).
In ovarian cancer cells, GnRH seems to have two opposite
activities:
1. The antimitotic activity through inhibition of signal transduc-
tion of mitogens such as epidermal growth factor, and
2. The inhibition of Doxorubicin-induced apoptosis via activa-
tion of transcription nuclear factor kappa B (NFkB) as shown
by Gründker et al. (2000). In this report is clearly suggested
that GnRH-a Triptorelin inhibits Doxorubicin-induced apop-
tosis via activation of NFkB.
Furthermore, biopsy specimens collected from lesions,
myometria and corresponding endometria of women with ovar-
ian endometrioma, adenomyosis and uterine myoma treated with
the GnRH-a, leuprolide acetate, for a variable period of 3–6
months before surgery, showed a significantly decrease in the infil-
tration of CD68-positive Mφ, micro-vessel density and tissue lev-
els of monocyte chemotactic protein I (MCP-I). Furthermore,
when compared with the non-treated group, a significant increase
in apoptotic index and quantitative-histogram scores of activated
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caspase-3 after GnRH-a therapy were observed in the eutopic
endometria, lesions and myometria of these diseases (Khan et al.,
2010).
Tanriverdi et al. (2005) demonstrated that GnRH-I and
GnRH-II have differential modulatory effects on human PBMC
proliferation and IL-2Rγ -chain mRNA expression in healthy
males. Treatment of in vitro PMBCs with GnRH-I and with
IL-2 resulted in a significant increase in cell proliferation as
well as in an increased expression of IL-2Rγ mRNA in a dose
dependent manner compared with the untreated control. In con-
trast, GnRH-II administration did not affect the proliferation of
PMBCs alone, and IL-2Rγ expression was significantly decreased
in all concentrations. This study clearly indicates the potential
stimulatory effects of GnRH-I in PBMCs and reduction of these
effects by GnRH-II.
Induces GnRH production by immune cells. Numerous interest-
ing and solid studies show that T-cells (and other immune cells)
can in fact produce and secrete various endogenous neurotrans-
mitters, either spontaneously or after induction by external stim-
uli. Among neurotransmitters produced by T-cells are GnRH-I
and GnRH-II (Levite, 2008).
Immunoactive and bioactive GnRH peptide is present and the
GnRH message is expressed in human peripheral blood T-cells.
Both CD4+ and CD8+ subsets of T-cells produce GnRH and it
is significantly increased when cells are activated by either phyto-
hemagglutinin or anti-CD3 antibody. This GnRH production in
activated T-cells is an early activation event that is independent of
IL-2 system activation and DNA synthesis (Azad et al., 1993).
Induces immunemediators production. To investigate the role of
GnRH in the modulation of T helper cytokines in pregnant rats
undergoing termination of pregnancy, Dixit et al. (2003b) admin-
istrated a GnRH-a to evaluate effects on Th-1 and Th-2 cytokines.
A marked increase in IFN-γ , inhibition of IL-4 production and
an IL-2 and IL-10 absent response was observed. It is possible that
IL-2 levels are unchanged because it might has been consumed by
activated T cells (Quintanar, 2011).
Recently, Goldberg et al. (2009) demonstrated in a clinically
relevant model of allogeneic bone marrow transplantation, that
after leuprolide acetate treatment, the enhanced peripheral T cell
reconstitution is due to both increases in lymphoid-committed
precursors as well as enhanced thymic regeneration.
GnRH has also been reported to regulate four angiogenic
chemokines expression (CXCL2, CXCL3, CXCL6, and CXCL8) in
human placenta, where trophoblasts were subsequently shown to
recruit lymphocytes. Additionally, in Jurkat T cells and primary
peripheral blood T and uterine NK cells; chemokine release was
detected in chemotaxis assays and this was shown to be GnRH
dependent (Cavanagh et al., 2009).
There are two works evaluating the efficacy of the GnRH-a,
leuprolide acetate, on NK cells activity in endometriosis. Results
are contradictory since the first one suggests an increased NK cell
activity in peripheral blood samples determined by 51Cr release
assay (Umesaki et al., 1999); and the second one reported that
NK cell cytotoxicity from control and patients was significantly
decreased with leuprolide acetate (Wong and Simon, 2004). These
findings suggest a direct immunomodulatory role of GnRH on
NK cell activity.
In an attempt to know the possible immunomodulatory effects
of GnRH on LPS activated human peripheral blood monocytes
cultured in vitro, Komorowski and Stepien (1995) found that
GnRH did not affect the secretion of the cytokines IL-1β and IL-6.
On the other hand, there is a report where the immunomod-
ulation exerted by GnRH on freshly isolated primary peritoneal
macrophages is clearly observed. In this work the authors found
that the production of nitric oxide, co-stimulated with LPS and
IFNγ , and the activity of NF-kB was suppressed by GnRH expo-
sure. Taken together, these results demonstrate that GnRH partic-
ipates in macrophage function and indicate that the NF-kB sig-
naling pathway may be responsible for GnRH-mediated immune
modulation (Min et al., 2009).
GnRH expression response against immune system challenges
There is a work that reported that when lymphocyte lysates
were applied to rat anterior pituitary cells in monolayer cul-
ture, significant stimulation of GnRH secretion was seen. This
response evoked by lymphocyte lysates was found to be dose
dependent and could be significantly inhibited by a GnRH-ant
(Emanuele et al., 1990).
Otherwise, TNF has a number of regulatory actions on
gonadotrophic functions: TNF and other cytokines, notably IL-
1β, have powerful LH suppressing abilities on pituitary activity
(Kalra et al., 1998).
GnRH and autoimmunity
Given that GnRH possesses direct immunostimulatory actions, it
has been hypothesized that GnRH might play a role in the devel-
opment of autoimmune disease.
Jacobson et al. (1994) demonstrated that the administration of
GnRH antagonists in a mouse model of systemic lupus erythe-
matosus (SLE), led to a reduction in autoantibody levels, total
immunoglobulin levels, renal disease, and significantly improved
survival, independently of gonadal steroids.
Based on the above mentioned findings and considering that
(1) in the nonobese mouse model of autoimmune diabetes (NOD
mouse), castration of male NOD mice leads to increased inci-
dence of diabetes, and that (2) castration of male mice leads to
an increase in GnRH action, Ansari et al. (2004) determined the
effect of GnRH agonists and antagonists on expression of autoim-
mune diabetes in this mouse model. Their results showed that
Antide administration prevented the increased incidence of dia-
betes, reduced total serum IgG levels, IL-6 cytokine expression
in cultured splenocytes, and the lymphocytic infiltration of islets.
GnRH administration exerted reciprocal effects, leading to earlier
timing of onset of diabetes and increased serum total IgG levels.
In addition, due to that has been reported that motoneu-
rons of spinal cord of rat from embryonic until adult stage,
express GnRHRs which respond to GnRH (Quintanar et al.,
2009) a possible clinical use in spinal cord injury
(Calderón-Vallejo and Quintanar, 2012) and CNS autoimmune
diseases has been proposed. Specifically, treatment with GnRH
(Quintanar, 2011) or a synthetic analog (Guzmán-Soto et al.,
2012) induces an improvement of clinical signs in the EAE
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model, where they remained significantly lower in EAE rats with
GnRH administration compared to animals without treatment.
In these experiments, also a significantly increased expression of
neurofilaments (NFs) and myelin basic protein as well as more
axons of larger areas in the spinal cord of EAE animals were
found.
A great advantage of GnRH and its analog leuprolide acetate, is
that they are capable to cross the blood brain barrier (Kastin et al.,
1980; Barrera et al., 1991) and reach their targets into the CNS.
Taking into account this advantage of leuprolide acetate and its
effect on recovery in locomotion and increased expression of bio-
logical markers, the use of this agonist as a potential therapeu-
tic approach for traumatic or neurodegenerative diseases such as
multiple sclerosis should be considered.
The effects of GnRH on immune system are summarized in
Figure 3.
FIGURE 3 | Summary of experimental data showing the effects of Gonadotropin-Releasing Hormone/Gonadotropin-ReleasingHormone agonist on
the immune system. Extrapituitary GnRH is implicated in a wide range of immunological processes, including direct cell immunomodulation and proliferative
responses (↑ = increase, ↓ = decrease).
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Clinical relevance and future directions
GnRH induces the secretion of FSH-LH and consequently of sex
hormones, which are involved in the immune response. Con-
troversial is the idea that sex hormones are immunoprotective
because depending on the type of hormone and experimental
conditions can be obtained opposite effects.
The presence of GnRH receptors and GnRH secretion by cells
of the immune system, opening the spectrum of possibilities for
interaction of autocrine or paracrine regulation. However, the
pharmacological use of GnRH or its analogues, independently of
the direct effect of sex hormones, raise the possibility that can
be used as a inflammatory regulator in autoimmune diseases.
Retrospective studies can be analyzed to establish whether treat-
ment with GnRH analogues have improved immunological con-
ditions of patients with autoimmune pathology. This option can
be explored in future works.
CONCLUSION
Hypothalamic hormones are closely related to the immune
system. Their direct and indirect effects establish a bidirec-
tional network to establish the required mechanisms to maintain
homeostasis.
TRH, CRH and GnRH exhibit common patterns of specific
receptors in immune cells and tissues. It is hard to think in
the action of a single independent factor within the neuroim-
munoendocrine network. When any of these elements desta-
bilize, the system is altered and is difficult to define which
factor of all may have been responsible for the alteration. Per-
haps because of the complexity of the network, experiments to
demonstrate such events become complicated to study. Using
in vitro models allow clarify in a specific manner some of
the elements involved in the homeostasis, however, extrapo-
late it to in vivo models could lead to unreliable interpreta-
tions.
In the evolution of the knowledge of the involvement of neu-
rohormones on the immune system, we can find that many of
the investigations are related to their pharmacological applica-
tion, however, few of them concern to the physiological mech-
anism of its immunomodulation either autocrine or paracrine.
If more is known about the physiology of these neurohormones,
expectations about their applications at therapeutic level or to
the understanding of our complex responses to internal or exter-
nal challenges to maintain the survival of the individual could be
proposed.
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